The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
VJVirtual | Targeting IL-2 in advanced NSCLC
Melissa Johnson, MD, Sarah Cannon Research Institute, Nashville, TN, discusses IL-2 immunomodulatory agents for advanced non-small cell lung cancer (NSCLC). Although IL-2-targeting agents have demonstrated substantial promise in treating NSCLC, they have also been associated with significant toxicity. Dr Johnson reviews the immunobiology of the IL-2 receptor to explain the resulting associated toxicity and suggests methods to reduce toxicity and enhancing efficacy. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
